MDGL - Madrigal Pharmaceuticals, Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

MDGL

MADRIGAL PHARMACEUTICALS, INC.

NASDAQ

$475.65

▼ DOWN 0.26% (-1.26)

KEY STATISTICS

Market Cap$11.02 B

52w High$615.00

52w Low$393.61

Dividend Yield—

Frequency—

P/E-37.16

Volume137.14K

Shares Out.23.10M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

William J. Sibold

COMPENSATION 2026

Salary$889,583

Stock Awards$7,558,495

Incentive Plan Pay$950,513

All Other Comp.$10,350

Total$12,214,250

ABOUT

SECTOR

Healthcare

WENT PUBLIC

February 6, 2007

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

915

PRICE TARGET

Target High$962.00

Target Low$542.00

Target Median$667.00

Target Consensus$680.38

UPCOMING EARNINGS

DateNov 3, 2026

DayTuesday

Rev. Est.$404.67M

NOV

TUE

SPLIT RECORD

DATE	TYPE	RATIO
2016-07-25	Reverse	1:35

ETFS HOLDING THIS STOCK

ETFS HOLDING

185

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

63.97%

HOLDERS

565

TOP 8 OF 565 · RANKED BY POSITION SIZE

Baker Bros. Advisors LP

2.1M sh

$1.15B

Janus Henderson Group Plc

Avoro Capital Advisors LLC

PRICE

$475.65 ▼ DOWN 0.26% (−$1.26)

OVERLAYS

About Madrigal Pharmaceuticals, Inc.

https://www.madrigalpharma.com ↗

Madrigal Pharmaceuticals, a clinical-stage biopharma in Pennsylvania, develops therapies for cardiovascular, metabolic, and liver diseases, with lead candidate resmetirom in Phase III for NASH.

INDUSTRY

Biotechnology

A PRODUCT MADRIGAL PHARMACEUTICALS, INC. IS KNOWN FOR

Rezdiffra (resmetirom)

Rezdiffra is the first FDA-approved once-daily oral medication for adults with MASH and moderate to advanced liver scarring, targeting the disease's underlying causes and addressing a significant unmet medical need.

COMPETITORS

COMPETITOR

LLY COMPARE

NVO COMPARE

VKTX COMPARE

Madrigal Pharmaceuticals in 2025

SENTIMENT: + POSITIVE

ANALYST CALL · DECEMBER 2025

Wave of Analyst Upgrades and Soaring Price Targets Propel Madrigal Stock to All-Time Highs in December 2025

In December 2025, Madrigal Pharmaceuticals experienced a surge in positive analyst sentiment, with multiple firms significantly raising their price targets. This culminated in a new high for the stock, driven by strong sales performance of their lead product, Rezdiffra, and strategic pipeline advancements.

PARTNERSHIP · JULY 2025 · IN PROGRESS

Madrigal Bets on Combination Therapy, In-Licensing Oral GLP-1 Agonist to Fortify MASH Leadership

Madrigal Pharmaceuticals made a decisive strategic shift to build a pipeline of combination therapies for Metabolic Dysfunction-Associated Steatohepatitis (MASH), anchored by its foundational drug, Rezdiffra. This was most significantly demonstrated by its exclusive global licensing agreement with CSPC Pharmaceutical Group for a preclinical oral GLP-1 receptor agonist, SYH2086 (later MGL-2086), positioning the company for the next wave of MASH treatment.

Latest News

GLOBENEWSWIRE · OCT 6, 2026

Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants

Secondary analysis of the Phase 3 MAESTRO-NASH trial demonstrated Rezdiffra improved histology and MRI-PDFF across common genetic variants associated with MASH progression CONSHOHOCKEN, Pa., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced the publication of a pre-specified secondary analysis from the Phase 3 MAESTRO-NASH trial in the Journal of Hepatology evaluating whether common genetic risk variants associated with MASH altered patient response to Rezdiffra® (resmetirom).

READ ARTICLE